The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

If and when approved by shareholders and regulators, the combined company will retain Pfizer's global operational headquarters in ... its generics business to Teva, which is expected to be ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

On Tuesday, Yum! Brands, a Fortune 500 company that has been based in Louisville since 1997, announced plans to create two new brand headquarters in the U.S. in Plano, Texas, and Irvine ...